Entera Bio ENTX 深 滬
等待開盤 09-17 09:30:00 美东时间
2.96
+0.100
+3.50%
華盛通- 最 高3.05
- 今 開2.86
- 成交量 77.75万股
- 最 低 2.785
- 昨 收 2.86
- 總市值 5.12亿
- 52周最高 4.20
- 市盈率 靜 --
- 換手率 0.45%
- 52周最低 0.91
- 委 比 54.34%
- 總股本 1.73亿
- 歷史最高 10.16
- 量 比 2.24
- 振 幅 9.27%
- 歷史最低 0.472
- 每 手 1
- 風險率 0.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket
Shares of Veea Inc (NASDAQ:VEEA) rose sharply in pre-market trading after the company announced a potential merger with NovaGen Group B.V. and a $10 million cornerstone investment from GeoNova Capital. Veea and NovaGen signed a term sheet to combine and are targeting execution of a definitive busine...
09-15 17:18
Oxford Industries Posts Mixed Q2 Results, Joins Asana, Lululemon Athletica And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq 100 futures gaining around 100 points on Friday. Shares of Oxford Industries Inc (NYSE:OXM) fell sharply in pre-market trading after the company reported mixed second-quarter financial results. Oxford Industries reported quarterly earnings ...
09-04 20:03
Entera to Participate in Upcoming Fall Investor Conferences
Entera Bio Ltd. announced that its CEO, Miranda Toledano, will participate in several fall investor conferences in 2026. The company focuses on developing oral peptide therapies for unmet medical needs using its proprietary N-Tab® technology. Its lead product, EB613, an oral PTH(1-34) tablet for osteoporosis, met Phase 2 endpoints. Entera also advances EB612 for hypoparathyroidism and other innovative therapies for obesity and rare conditions.
08-27 12:00
Entera Bio appoints new chief medical officer
The latest announcement is out from Entera Bio ( ($ENTX) ). On August 18, 2026,...
08-18 20:29
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Entera Bio Ltd. has appointed Riccardo Camisasca, M.D., as its Chief Medical Officer. With over 30 years of experience in global pharmaceutical research and clinical development, Dr. Camisasca previously served as Global Head of Research & Development at Sumitomo Pharma Switzerland. His expertise will strengthen Entera’s clinical execution team and support the upcoming Phase 3 initiation of EB613, an oral anabolic treatment for osteoporosis. Dr. ...
08-18 12:00
Entera Bio Announces That Post-Hoc Data From Its Phase 2 Clinical Trial Of EB613Has Been Selected For Two Presentations At The American Society For Bone And Mineral Research Annual Meeting
Two presentations including the Plenary Poster Presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9–12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts. Plenary Posters are highly ranked poster ...
08-04 20:32
美股牛股 | QBTS飙升20%，与AT&T达成量子计算合作；奥麦罗制药劲升15%，阿斯利康竞品药物3期临床试验失败
QBTS飙升20%，与AT&T达成量子计算合作；奥麦罗制药劲升15%，阿斯利康竞品药物3期临床试验失败；BMNR大涨13%，旗下以太坊价值已超公司原本市值>>
07-28 18:45
Entera Bio prices $275M private placement
Entera Bio (NASDAQ:ENTX) said on Monday it priced an oversubscribed $275M private placement led by existing investor BVF Partners, with participation from several healthcare-focused institutional inve...
07-27 20:59
Entera Bio Enters Into Securities Purchase Agreement For Oversubscribed Private Placement Financing, Expected To Result In Aggregate Gross Proceeds Of ~$275M
Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH(1-34) peptide tablet in development for the treatment of osteoporosis TEL AVIV, July 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASD...
07-27 20:33
Entera Bio Expands Share Authorization and Equity Plans
Entera Bio ( ($ENTX) ) has issued an announcement. At its 2026 Annual Meeting o...
07-17 17:15
